Drug intelligence / Profile preview

bifidobacterium breve CNCM I-4035

Development stage: Preclinical
Lead developer: Hero
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve CNCM I-4035 is a proprietary probiotic strain isolated from the feces of exclusively breast-fed infants. It is investigated for its effects on gut and immune health. This strain exhibits immunomodulatory and anti-inflammatory properties: it can modulate cytokine production by human intestinal dendritic cells, inducing both pro- and anti-inflammatory cytokines such as IL-6, IL-8, TNF-α, and IL-10, and is also reported to enhance gut immunoglobulin A (IgA) secretion and alter gut microbiota composition. The strain's cell-free culture supernatant (metabolites released into the medium) has demonstrated anti-inflammatory effects, including the down-regulation of pro-inflammatory pathways in response to pathogenic stimulation (such as Salmonella typhi), with increased activation of Toll-like receptor 9 signaling. Animal models suggest it may help reduce gut and systemic inflammation and promote mucosal immune tolerance[2][3][4][6][7][8].

Targets

TLR9 (Toll-like receptor 9)BSH (Bile salt hydrolase)

Beyond the preview

Go deeper on bifidobacterium breve CNCM I-4035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium breve CNCM I-4035.

Explore the full profile